BioInsights - Vaccine R&D in the post-COVID-19 era

Vaccine R&D in the post-COVID-19 era

Vaccine Insights 2022; 1(1), 79–84

DOI: 10.18609/vac.2022.014

Published: 29 May 2022
Interview
Philip Dormitzer

Having played a key role in the development of Pfizer’s mRNA COVID-19 vaccine, Philip Dormitzer is now heading up vaccines R&D at GSK – we sat down with him to discuss speeding up vaccine development, the future of RNA vaccines, and how the pandemic has shaken up the industry.

Philip Dormitzer recently joined GSK as Global Head of Vaccines Research and Development. Previously, he was Chief Scientific Officer for Viral and RNA Vaccines at Pfizer, where he led programs that included the Pfizer-BioNTech RNA-based COVID-19 vaccine collaboration. Previously, he held positions at Novartis Vaccines that included Head of US Research and was the founding member of the Novartis Viral Vaccine Research Center in Cambridge, MA. In 2009, his research team supported the development and licensure of three H1N1v influenza pandemic vaccines in what remains the most rapid vaccine response in history. Before joining industry, Dr Dormitzer was an Assistant Professor of Pediatrics at Harvard Medical School and led a structural virology laboratory, which, with collaborators, determined the structures of the rotavirus neutralization antigens.